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1. Introduction 
Type 1 Diabetes is an intrinsically unstable condition. A small group of patients with Type 1 
Diabetes (3‰), mainly young women, suffer chronically by poor metabolic control, 
characterized by a severe instability of glycemic values with frequent and unpredictable 
hypoglycemic and/or diabetic ketoacidosis episodes which cannot be attributed to patients 
or clinicians errors. The quality of life of these patients is dramatically compromised in 
particular because of the frequency of acute events, hospital recoveries and precocious 
appearance of chronic complications. This clinical condition has been defined as "brittle 
diabetes" (Tattersall, 1977).  
A precise quantification of these patients is difficult because diagnostic criteria are still not 
well defined and it is often difficult to verify errors of patients in terms of inappropriate 
conduct with the pathology. Metabolic instability is manifested most obviously by chaotic 
glycemic profiles, which show greater and more unpredictable variation than in “stable” 
patients with diabetes. Patients with brittle diabetes cannot be controlled adequately, even 
by closely supervised, intensive insulin regimens, including continuous subcutaneous 
and/or intravenous insulin infusion (Bertuzzi et al., 2007).  Their care is often very 
expensive of time and resources, and their lives are constantly at risk from metabolic 
catastrophe. Management of these patients can also be frustrating and demoralizing for all 
concerned, including the patient’s family and associates and the diabetes care team.   
This review will focus on a contemporary “painting” of brittle diabetes beginning with a 
few historical notes leading to its definition, ongoing researched pathophysiologic substrate, 
common and life-threatening clinical manifestations, diagnosis and treatment.   
2. Brittle diabetes: Historical notes 
In 1942 the Chicago physician Woodyatt suggested that “The history of diabetes has been 
marked by recurrence of certain ideas which decline and disappear; only to go through a 
similar cycle again in an altered form in the new generation” (Woodyatt, 1942). This is 
particularly true of the concept of brittle diabetes which Woodyatt himself introduced in the 
1940s. Although, he never wrote a paper on the subject, contemporaries understood it to 
refer to excessive fluctuations of blood sugar which could not be otherwise explained; the 
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cardinal feature of brittle diabetes was unpredictability and unexpected hypoglycemic 
reactions. Also in the 1940s, practitioners of the newly formed psychosomatic movement 
took an interest in the effect of emotional factors on the course of diabetes and, in particular, 
patients who were “difficult” or “refractory”. “Difficult” patients were marked by not 
following their doctor's instructions or having recurrent diabetic ketoacidosis.  
By the 1950s the question was whether there were two distinct groups of patients; one 
whose lability could be cured by adjusting insulin, diet, and exercise, and another whose 
lability had an emotional origin. It remained a question whether in those patients in whom 
glycemic lability was attributed to an emotional cause, were in fact experiencing 
psychosocial problems as a consequence rather than a cause of the metabolic instability. 
Patients with factitious hypoglycemia, which remained undetected for weeks, suggested 
that neither close observation nor screening by a psychiatrist could rule out the factitious 
disease (Tattersall, 1997). Therefore in 1977 the definition of brittle diabetes was suggested 
by Tattersall for patients whose life was “constantly disrupted by episodes of hypo- or 
hyperglycemia, whatever their cause should be”. This was widely accepted and there was a 
subtle shift towards regarding brittle diabetes as synonymous with recurrent ketoacidosis.  
In the 1980s several groups investigated large series of such patients, using new methods to 
try to uncover a biochemical basis such as defective insulin absorption, accelerated 
degradation at insulin injection sites, and inappropriate secretion of various 
counterregulatory hormones (Schade et al., 1980; Fischer et al., 1980). Most of these patients 
were young overweight women and the eventual conclusion was that in most patients the 
instability was self-induced. In the 1980s recurrent, often warningless, hypoglycemia was 
recognized as a problem in its own right but in the current era it was reborn as also a 
problem of insulin pharmacokinetics, exact as Woodyatt originally conceived it. 
3. Aetiology and pathophysiologic substrate: From the suspicion to ongoing 
research  
Going back in literature, among the main causes of “brittleness” referenced are 
malabsorption, certain drugs (i.e. antipsychotics), defective insulin absorption or 
degradation, defect of hyperglycemic hormones especially glucocorticoid and glucagon, and 
above all delayed gastric emptying as a result of autonomic neuropathy (Vinik et al., 2003; 
Lehmann et al., 2003; Voulgari et al., 2010). Moreover, possible causes of hypoglycemic 
“brittleness” described are organic problems which comprise lost hypoglycemia warnings 
(Tattersall & Gill, 1991), such as alcohol abuse (Hepburn et al., 1990), renal failure, 
gastroparesis, hypopituitarism, and senile dementia (Potter et al., 1982). 
Variable adherence to insulin treatment contributes to presentation of brittle type 1 diabetes 
in adolescents and young adults. The deterioration in glycemic control observed in patients 
aged 10-20 years is often associated with a significant reduction in the adherence index (the 
medically recommended insulin dose and cumulative volume of insulin prescriptions 
supplied for the calculation of the days of maximum possible insulin coverage per annum). 
The latter is inversely related to hospital admissions for diabetic ketoacidosis and all 
hospital admissions related to acute diabetes complications in young (<20 years) type 1 
diabetes patients (Morris, 1990). Direct evidence of poor compliance with insulin therapy in 
young patients with type 1 diabetes and poor adherence to insulin treatment is a major 
factor that contributes to brittle diabetes with diabetic ketoacidosis in this age group. 
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Insulin requirements that apparently exceed 2.0 U/kg/day almost always indicate an 
underlying problem and frequently are suggestive of “brittleness”. Causes of apparent or 
genuine insulin resistance in type 1 diabetes patients include: puberty (Amiel, 1996), 
overinsulinization (Rosenbloom & Giordano, 1977), the Mauriac Syndrome (Elder& 
Natarajan, 2010), chronic infections of the diabetic foot (Tentolouris et al., 1996; Tentolouris 
et al., 2010, Papanas & Maltezos, 2009), acromegaly (Elkeles et al., 1969), Cushing’s 
Syndrome (Anagnostis et al., 2009), thyrotoxicosis (Jacobson et al., 1970) and 
phaeochromocytoma (Ishii et al., 2001). In few cases of recurrent diabetic ketoacidosis, there 
is some suggestion of a deliberate manipulation of diabetes control: patients with recurrent 
diabetic ketoacidosis are thought to be attention-seeking by omitting insulin due to marital 
problems and possible depression, and possibly personal gain from diabetic instability 
(Benbow et al., 2001); depression and manipulation are among the contributory factors to 
instability as well as chronic non-diabetic medical disease (Gill, 1992). 
The aetiology of recurrent hypoglycemia includes impaired awareness of hypoglycemia, 
which can be associated with long-standing type 1 diabetes (Ryder et al., 1990), or induced 
by antecedent hypoglycemic episodes (Lager et al., 1986; Janssen et al., 2000), 
overinsulinization (Widom & Simonson, 1992), endocrinopathies (Hardy et al., 1994), and 
gastrointestinal diseases such as self-induced vomiting by patients with anorexia and/or 
bulimia (Lloyd et al., 1987; Stancin et al., 1989; Crow et al., 1999). Malabsorption, including 
celiac disease as it is analyzed later, which is associated with type 1 diabetes, can also cause 
decreased insulin requirements and unexpected and sometimes severe hypoglycemic 
episodes (Smith et al., 2000). Psychiatrically and psychological problems are more common 
than suspected.  Psychosocial factors are very important and factitious “brittleness” may 
lead to a self-perpetuating condition. The factors reported are: as previously mentioned 
poor compliance (Pickup et al., 1983), family dysfunction (Diabetes Control and 
Complications Trial Research Group, 1993) and obsessional control of diabetes (Borch-
Johnsen & Helweg-Larsen, 1993). Psychological problems (Tattersall & Gill, 1991), "life 
chaos" (Hepburn et al., 1990), factitious insulin overdose (Hepburn et al, 1990) and anorexia 
nervosa (Potter et al., 1982) also illustrate the aetiologic profile of hypoglycemic 
“brittleness”. Suggested motives include escape from hostile situations to the security of 
hospital, attention seeking, and revenge on self or family and suicidal intent. Some patients 
induce hypoglycemia to”feel high” (Cassidy et al., 1999). Rarely cases of factitious overdose 
where insulin was given in excessive doses by a mother to her diabetic child (Munchausen's 
Disease by Proxy) are also referenced (Ludviksson et al., 1993; Gill & Lucas, 1999).  
Acute psychological stress plays a role in the glycemic instability of some patients with 
brittle type 1 diabetes through an increased secretion of insulin-counteracting hormones. 
Psychological interviews showed that most patients with brittle diabetes perceive a link 
between life stress and their blood glucose control and they have much more difficulty in 
verbalizing their emotions (Dutour et al., 1996; Scantamburlo et al., 2001). Patients with 
brittle diabetes display distinct cardiovascular and neuroendocrine responses to 
psychological stress, as well as distinct psychological profiles (Jørgensen, 2007). Moreover, 
hormonal response to an acute psychological stress is more pronounced in brittle diabetes 
and might be one of its pathogenic factors (Dutour et al., 1996).  
Psychosocial parameters interact with metabolic instability even in juvenile brittle type 1 
diabetes. Feelings of dominance precede an increase of blood sugar variance, whereas 
depressive moods, anger and body symptoms are associated with metabolic instability 
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(Brosig et al., 2001). A family therapy session also results in an increase of the mean blood 
sugar variance. Multivariate time-series is a mean to demonstrate psychosomatic 
interrelations and may also contribute to an empirically rooted understanding of 
psychodynamic processes in psychosomatoses.  
Schizophrenia, like other autoimmune disorders, is likely a heritable phenomenon, and a 
genetic liability in this disorder is hardly disputed. Research has indicated that physiologic 
connections between IFN-gamma and TNF-alpha are suggestive of a connection between 
the symptoms associated with schizophrenia and those of hypoglycemic events in type 1 
diabetes patients (Kane et al., 2009). Autoimmune pathogeneses of schizophrenia have been 
hypothesized and the clinical delineation of a potentially corresponding subset of patients 
has been addressed in young female patients who carry the concomitant diagnoses of 
schizophrenia, brittle type 1 diabetes, and hypothyroidism. These patients when treated 
with corresponding antipsychotic medication on an acute basis, an apparent resolution of 
their brittle type 1 diabetes with the successful treatment of their psychotic disorder is 
observed (Balter et al., 2004; Ramaswamy et al., 2006). This well documented link between 
antipsychotic agents and changes in blood glucose may be of benefit in a subset of patients 
who suffer from both psychotic and diabetic disorders.   
In autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy, autoimmune 
destruction of the pancreatic beta-cells with development of brittle type 1 diabetes is possible, 
but rarer than in the other polyglandular autoimmune syndromes (Lankisch et al., 2009). The 
pathogenesis of this unique autoimmune disease is unknown (Vogel et al., 1992). However, 
cases of young female patients with the diagnosis of autoimmune polyendocrinopathy, 
candidiasis and ectodermal dystrophy have been presented and characterized by 
psychosomatic abnormal development, teeth alterations, post-puberal gonadal failure with 
dystrophic hypoplasia of external genitalia, previous vaginal candidiasis, and slowly 
developing juvenile brittle diabetes with an early onset and severe complications (Iannello et 
al., 1997). Such patients (and their female maternal relatives) need a long-term follow-up in 
order to evaluate the function of endocrine glands and to initiate early treatment for hormonal 
deficits, as well as to detect the non-endocrine components of disease.  
Most patients with brittle diabetes are in the second or third decade of life and they are 
typically admitted with diabetic ketoacidosis rather than hypoglycemia or mixed patterns of 
instability. A “second peak” of prevalence at the age of 60-70 years has been recorded 
though much smaller than the main peak at 15-30 years (Gill et al., 1996). Causes for this 
“second round” of “brittleness” include medical disease (14%), hypoglycemic unawareness 
(6%), and memory or behavioral problems (8%).  
Brittle diabetes in older (≥70 years) patients with a history of insulin therapy using mainly 
human recombinant insulin is reported and is attributed to a high titer of insulin antibodies 
and a higher level of insulin resistance (Park et al., 2008). Steroid pulse therapy reduces the 
possible effect of the insulin antibodies on insulin resistance and glycemic instability, 
successfully decreases their titer and binding capacity, increased glucose infusion rate and 
improved glycemic control with reduced blood glucose excursion (Matsuyoshi et al., 2006). 
Alteration in insulin pharmacokinetics induced by insulin antibodies seems to be a cause of 
brittle diabetes. Steroid treatment might be useful for the improvement of glycemic control 
in such patients. 
Brittle diabetes in the elderly patients with diabetes is most frequent characterized by 
recurrent hypoglycemia (Benbow et al., 2001). In elderly patients with brittle diabetes, 
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contributing factors to instability are chronic, nondiabetic medical diseases. Unrecognized 
celiac disease is one such chronic disorder and recurrent hypoglycemia is ameliorated by 
adherence to a gluten-free diet, when coexisting colorectal disease has been ruled out by 
barium enema and colonoscopy. The fact that 19% of patients with adult celiac disease could 
be in the above 60 years of age group should alert us to the possibility of an association with 
brittle diabetes in older age as well (Mody et al., 2003). Furthermore, in the presence of 
otherwise unexplained brittle diabetes, the coexistence of iron-deficiency anemia should 
heighten suspicion, since this haematinic deficiency is the commonest extraintestinal 
manifestation of celiac disease with distinct episodes of microcytic and/or hypochromic 
anemia, responsive to iron supplements (Jolobe  & Khin, 2002; Hershko & Skikne, 2009).  
Brittle diabetes in the extremely elderly patients with diabetes (>80 years) is thought to be a 
depletion of endocrine insulin secretion due to marked beta-cell reduction and/or beta-cell 
exhaustion secondary to long term diabetes duration. It is usually characterized by frequent 
striking hypoglycemic episodes without clinical awareness. These patients often are 
presented with vascular dementia, visual disturbances, hearing difficulties and speech and 
motor disturbances. Daily detailed observation is required to care for such patients with 
brittle diabetes (Kawanishi  & Miyashita 2003). 
Sometimes, there is no obvious cause. Most patients with “idiopathic” brittle diabetes that 
oscillates between hypoglycemia and hyperglycemia have no obvious underlying cause, but 
many deliberately induce glycemic instability by interfering with their treatment. 
Nonetheless, organic causes of brittle diabetes are occasionally found and must always be 
sought, i.e. recurrent infections, especially if insulin dosage is not increased (Laffel et al., 
2006; Voulgari & Tentolouris, 2010), endocrinopathies, i.e. hypoadrenalism (Gill & Williams, 
2000), inappropriate treatment regimens or lifestyle, and pancreatic damage.  
Diabetes after total pancreatectomy is commonly described as “brittle” with most series 
reporting outcomes after resection for pancreatitis alone (Jethwa et al, 2006).  Brittle diabetes is 
also frequently developed in patients with chronic pancreatitis after partial pancreatectomy 
and its development is partially related to reduced pancreatic beta-cell area (Meier et al., 2009), 
as well as other clinical variables, i.e. pre-operative fasting glucose levels, HbA1c and body 
mass index (Schrader et al, 2010). This is further highlighted by the fact that different surgical 
procedures have an unequal impact on glucose control. Insulin secretion is diminished after 
pancreatic-head and pancreatic-tail resection, but post-challenge glucose concentrations can be 
ameliorated only after pancreatic-head resection (Menge et al., 2009).  
Brittle diabetes in chronic pancreatitis due to the gradually loss of pancreatic parenchyma 
and the appearance of calcifications and of steatorrhea, is characterized by a high risk of 
hypoglycemia due to the decreasing output of insulin and glucagon. In most instances, 
measurement of fecal concentration of elastase may be sufficient to diagnose exocrine 
pancreatic insufficiency (Layer & Keller, 1999). Fecal fat analysis is useful to establish 
malabsorption and to monitor pancreatic enzyme replacement therapy (Dobrilla, 1989). 
Modern pancreatic preparations are also engineered and most patients reduce their 
steatorrhea, although in selected cases larger doses may be needed, depending on size of the 
meal and the severity of the disease. Efficacy of enzyme replacement therapy is influenced 
by the presence of diabetes and vise-versa (Hammer, 2010).  
Acute tropical calculous pancreatitis was also reported as generative of brittle diabetes and 
oral pancreatic enzyme therapy was used for the glycemic control with favorable results 
regarding HbA1c, and fasting glucose levels (Mohan et al., 1998).  
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Recently, impaired metabolism of intestinally derived chylomicron remnants has been 
implicated in the development of atherosclerosis. A specific marker of chylomicron particle 
number (apoB48) has been associated with increased vascular disease such as obesity, 
metabolic syndrome, type 2 diabetes, and familial hypercholesterolemia (Otokozawa et al., 
2009; Valdivielso et al, 2009). The role of these particles in the increased atherosclerotic risk 
associated with brittle type 1 diabetes is currently demonstrated. ApoB48 metabolism is 
shown to be altered in individuals with brittle diabetes even in the absence of classic 
dyslipidemia (Su et al., 2009). Disturbed plasma apoB48 remnants can potentially predict 
coronary artery disease in this population. Among the newest pathogenetic theories 
demonstrated is that plasma glucose levels in patients with brittle type 1 diabetes respond 
directly to the amount of transient electromagnetic fields (“dirty electricity”) generated by 
everyday electronic equipment and wireless devices in their environment (Havas, 2008). In 
an electromagnetically clean environment, patients with type 1 diabetes require less insulin 
and have lower levels of plasma glucose (Li, 2005; Beale et al., 1997). Exposure to 
electromagnetic pollution in its various forms may explain the difficulty in glycemic control 
in patients with brittle diabetes who suffer from symptoms of electrical hypersensitivity 
(almost 35%). Reducing exposure to electromagnetic pollution by avoidance or with 
specially designed GS filters may enable some patients with diabetes to better regulate their 
blood sugar with less medication (National Toxicology Program, 2010). Figure 1 illustrates a 
summary of the cited causes of Brittle Diabetes. 
4. Diagnosis and clinical manifestations  
There are no universally agreed diagnostic criteria. Three forms of brittle diabetes have been 
described: recurrent diabetic ketoacidosis, predominant hypoglycemic forms and mixed 
instability (Figure 1). Previous studies have shown that over 90% of hospital admissions in 
patients with recurrent diabetic ketoacidosis or recurrent hypoglycemia are due to that 
particular type of glycemic instability (Gill, 1992). Hypoglycemic brittle diabetes makes up 
17% of the total brittle spectrum, compared with 59% of ketoacidosis brittleness (Tattersall, 
1991) and 24% (Gill, 1992) of mixed brittleness. Compared with patients with recurrent 
diabetic ketoacidosis, hypoglycemic brittle patients are significantly older; and are of 
approximately equal male: female ratio, compared with a female excess in recurrent diabetic 
ketoacidosis (Gill & Lucas, 1992). Also of interest is that patients with mixed brittleness are 
intermediate in both age and sex-ratio, between the groups with recurrent diabetic 
ketoacidosis and recurrent hypoglycemia. Idiopathic brittle diabetes is a label applied to 
those patients who remain poorly controlled despite modern intensified insulin regimens 
and have no obvious cause for their instability (Somogyi, 1959). Most display a pattern of 
general hyperglycemia with wide glycemic swings and recurrent episodes of ketoacidosis.  
A scheme for investigating patients suspected for brittle diabetes is suggested in Figure 2. A 
thorough history and examination may elucidate drug-induced causes, infections or 
endocrine conditions (including puberty). Before moving on to more detailed investigations, 
the patients understanding of diabetes monitoring and treatment should be assessed. It 
should be reasonable to exclude chronic infections and specific endocrine diseases. If 
considered necessary insulin antibodies and insulin receptor antibodies should be 
measured. Should no cause for insulin resistance emerge, the possibility of factitious insulin 
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Fig. 1. Causes of Brittle Diabetes 
 
 
Fig. 2. The spectrum of Clinical Manifestations of Brittle Diabetes in Type 1 Diabetes Patients  
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resistance should be explored and an insulin challenge test should be performed (Serlin & 
Lash, 2009).  Most patients who remain undiagnosed at this stage probably have factitious 
disease and may be skilled at manipulating their treatment, their families and physicians. 
Therefore, the test injections must be given by a member of the diabetes care team under 
conditions that guarantee the patients’ cooperation. The need this must be explained to both 
patients and family. Hospital admission in such cases can provide formal psychological and 
psychiatric assessment of the patient and the family, without which investigation and 
management are incomplete. 
It is essential to follow a logical protocol that initially excludes potentially remediable, 
organic causes. Cases remaining unexplained at the end of the process are most likely to be 
factitious in origin. Close observation during hospitalization is important: some brittle 
diabetes patients are skilled at stimulating hypoglycemia, possibly to gain attention or 
simply to obtain food that they desire (i.e. sweets) that are otherwise prohibited.  
 
Fig. 3. Scheme for investigation of Brittle Diabetes  
Among the life-threatening clinical manifestations, cases of spontaneous muscle infarction 
in young (mainly ≤30 years) women with a short duration (≤5 years) history of brittle type 1 
diabetes that was not complicated by nephropathy, retinopathy or neuropathy have been 
described in the literature (Virally et al, 2007). 
Spontaneous muscle infarction is a rare complication of diabetes, usually described in 
patients with multiple long-term diabetic complications (Woolley & Smith, 2006). Diabetic 
muscle infarction is more frequent in women (61.5%) and in type 1 diabetes (59%). The 
mean age of reported cases is 42.6 years, with a mean duration of diabetes of 14.3 years 
(Mathew et al., 2007). Multiple complications are usually present: 71% of patients have 
nephropathy (Madhan et al., 2000), 57% have retinopathy, and 54% suffer from autonomic 
neuropathy (Trujillo-Santos, 2003). Spontaneous diabetic muscle infarction is presented with 
necrosis of all muscle elements, with polymorphonuclear or mononuclear cellular 
infiltration and a varying but often limited degree of regeneration, depending on the age of 
the lesion. The presentation is usually acute, with pain and swelling localized to the thigh in 
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most instances. Systemic signs such as pyrexia are infrequent. Laboratory tests (such as 
white cell count and creatinine kinase) and plain radiographs are not helpful, although the 
erythrocyte sedimentation rate is often elevated. The diagnosis, in the appropriate setting, is 
strongly suggested by magnetic resonance imaging, which shows increased signal intensity 
and asymmetry of the muscle on T2-weighted scanning as well as fluid in the tissue planes. 
Management consists of resting the muscle, analgesics, and gradual mobilization. 
Recurrence is common and may be seen in more than 50% of the patients. Long-term 
prognosis is poor, with most patients dying from cardiovascular complications of diabetes 
within 5 years of diagnosis. Therefore, a high index of suspicion, when a poorly controlled 
patient with diabetes presents with non-traumatic limb pain is needed (Mathew et al., 2007). 
All common causes of muscle infarction should be excluded, particularly microangiopathy 
and a hypercoagulable state. The differential diagnosis includes infection (pyomyositis, 
necrotic fasciitis), focal inflammatory myositis, vascular events, trauma, tumor and diabetic 
amyotrophy (Grigoriadis et al., 2000). When all of these are excluded, the possibility that the 
alternating states of transient acute hypoglycemia and hyperglycemia may be responsible 
for the myocardial infarction should be aroused and brought to the diagnostic table. 
“Brittleness” usually resumes after treatment with subcutaneous insulin infusion using a 
portable pump and no recurrence of muscle infarction is observed during the follow-up. 
Although, integration of the patient's mental organization is an important part of all 
psychotherapeutic experiences and generally it is welcomed and thought well worth the 
effort needed to achieve it, however patients with brittle diabetes feel terrified by this 
process (Tallandini, 1999). They seem to think that integration involves a loss of the self: 
they feel it is dangerous and even resist it with psychotic-type defenses. For them, this 
reaction is always activated by separation, and it also appears prior to any developmental 
step they need to take- i.e. in recognizing self-boundaries, sexual identity, and facing the 
oedipal conflict. On all these occasions their reaction is to run away from treatment in a state 
of deep regression, feeling suicidal, and liable to seriously harm their self through the 
mistreatment of their diabetes (Hoffman, 2003).  
Patients with long standing brittle diabetes with numerous episodes of diabetic ketoacidosis 
and frequent hypoglycemic episodes may present significant pathological changes in the 
gastric wall that affect all major components including muscle, neurons and interstitial cells of 
Cajal. Gastroparesis and severe malnutrition can occur in the presence of these changes, and 
may reflect vagal, central or hormonal influences (Pasricha et al., 2008). In juvenile brittle 
diabetes early diagnosed (in the first days of life) it is possible to develop severe secretory 
diarrhea. Extensive biochemical and serological investigation often fails to reveal the etiology 
of the diarrhea. Therapeutic trials with various agents (i.e. loperamide, cholestyramine, 
prednisone, indomethacin, and somatostatin analogue) often have no response. In some cases 
death from septicemia and malnutrition related to diarrhea and poor control of glycemia is 
reported before the completion of 1 year of age (Jonas et al., 1991; Roberts & Searle, 1995). 
Autopsy, may reveal absence of islets of Langerhans in the pancreas, and diffuse dysplastic 
changes in small and large intestinal mucosa. The entire alimentary tract may be lined by 
epithelia most typical of foregut mucosa: secretory-type glands, absent crypts of Lieberkuhn, 
and absent villi relating brittle type 1 diabetes with diffuse intestinal dysplasia independently 
or as part of a hyperimmunoglobulin syndrome (Peake et al., 1995). 
Inhibition of the periodontal ligament cells which are the most important cells in the healing 
of wounds and the regeneration of periodontal tissues is the key explanation for the delayed 
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periodontal regeneration and healing in patients with brittle diabetes with recurrent diabetic 
ketoacidosis (Kim et al., 2006). This is relevant to the increased number of infections that 
compromise more distant structures (via direct spread and distant spread), i.e. intracranial, 
retropharyngeal and pulmonary pleural infections and the dissemination by bloodstream 
that can lead to primary rheumatic problems and secondary deposits on the valves of the 
heart, i.e. endocarditis (Jiménez et al., 2004; Lazow, 2005).  
Pulmonary edema, cerebral edema and multiple infarctions of the brain and cervical spinal 
cord develop more frequent in brittle type 1 diabetes than in “stable” type 1 diabetes 
patients during diabetic ketoacidosis, despite appropriate treatment. This may result in 
spastic quadraparesis and permanent disability (Dixon et al., 2006).  
Some of the cutaneous manifestations of brittle diabetes include necrobiosis lipoidica 
diabeticorum, diabetic dermopathy, scleredema adultorum and acanthosis nigricans 
(Jabbour, 2003). 
5. Quality of life: Struggling towards its achievement  
The disruption of life, which is fundamental to the definition of brittle diabetes, obviously 
dependents on the patient’s usual lifestyle and on numerous independent factors, including 
the admission policy of the diabetes care team. Emergency admissions due to poor diabetic 
control are much more common and prolonged than in “stable” patients, and it is not 
unusual for patients with brittle diabetes to spend several months each year in hospital. 
Pragmatic definitions of lifestyle disruption and “brittleness” include frequency and 
duration of hospitalization, more frequent psychosocial disruptions, pregnancy 
complications (Kent et al., 1994; Gill et al., 1996) and higher risk of death due to diabetic 
ketoacidosis, hypoglycemia, and renal failure (Tattersall et al., 1991).  
Epidemiological studies in patients with brittle diabetes have established higher prevalence 
rates of psychiatric disorders, in particular mood and anxiety disorders. However, the 
prevalence rate and symptom profile of depression was found to be homogeneous between 
psychiatric patients with or without diabetes (Eiber et al., 1997).  
Health-related quality of life is among the benefits of islet transplantation, because of a 
significant improvement in the dimensions of satisfaction and impact of diabetes 
(Benhamou et al., 2009). Therefore, its assessment may help in the selection of candidates 
with brittle diabetes for islet transplantation. 
6. Management strategies in brittle diabetes  
6.1 Qualification of glycemic variability  
Several measures have been developed to quantify metabolic instability in brittle diabetes, 
which include assessment of the Mean Amplitude of the largest Glycemic Excursions 
(MAGE), the Mean of Daily Differences (MODD), Lability Index (LI), Low Blood Glucose 
Index (LBGI), Clarke's score, Hyposcore, and continuous blood glucose monitoring 
(Vantyghem & Press, 2006).  
6.2 Continuous glucose monitoring systems: Indications, advantages, and limitations  
Accurate and reliable devices sensing glucose on a near-continuous basis may facilitate 
specific therapeutic adjustments that need to be made to avoid hypo- and hyperglycemic 
excursions, thereby improving metabolic control. Patients with brittle diabetes, who are 
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motivated to participate in their diabetes care and are technologically adept, may benefit 
from continuous glucose monitoring. Current continuous glucose monitoring systems 
indicate the glucose level, the direction and magnitude of change of glucose levels, and can 
be used to assess glycemic variability (De Block C et al., 2008). In addition, real-time 
continuous glucose monitoring sensors can serve as a tool to predict impending glucose 
excursions, thereby providing alarm signals of hypo- and hyperglycemic values warning the 
patient to take preventative actions (De Block C et al., 2008). Quality of life may also 
improve by using continuous glucose monitoring via reducing the fear of hypoglycemia 
(Weinzimer et al., 2004).  
However, to successfully implement continuous glucose monitoring in daily practice, these 
devices must be accurate and reliable, and one must be aware of the limitations of current 
continuous glucose monitoring systems, that originate from physiological and technical 
aspects. Whether continuous glucose monitoring succeeds in ameliorating metabolic control 
and in reducing hypoglycemic episodes, as well as whether it improves quality of life in 
patients with brittle diabetes remains to be proven. Should this be the case, real-time 
continuous glucose monitoring may reduce chronic diabetic complications, and avoid 
hospitalizations, thereby reducing health care costs.  
7. Treatment options 
Therapy of brittle diabetes is based on education, glycemic control, intensive treatment and 
strict interaction between physicians and patients. Once psychogenic problems have been 
excluded, therapeutic strategies require firstly, the treatment of underlying organic causes of 
the “brittleness” whenever possible and secondly optimizing standard insulin therapy using 
analogues, multiple injections and consideration of continuous subcutaneous insulin 
infusion. However, patients with brittle diabetes characterized by recurrent diabetic 
ketoacidosis are often not improved by continuous subcutaneous insulin infusion, although 
there may be exceptions (Pickup & Keen, 2002). The introduction of insulin analogous, with 
either ultra-fast or ultra-slow action and the use of subcutaneous insulin pumps have 
significantly increased the possibility of treating most of these cases. However, there is a 
minority of patients resistant to therapy and alternative approaches are needed for these 
most severely affected patients. In similar cases, pancreas or islet transplantation represents 
an effective therapeutic option entailing good expected outcomes.  
7.1 Lifestyle and education 
Reduction of the rate of severe hypoglycemia has been noted with the Dose Adjustment for 
Normal Eating, a modern approach of advocating dietary freedom and appropriate 
flexibility of insulin doses, resulting in improved long-term metabolic control and better 
adherence to treatment goals (McIntyre, 2006).  
The patient’s ability to manage his or her own diabetes should be evaluated and reinforced 
if necessary, and guidelines drawn up with the patient’s agreement for future treatment 
targets and follow-up. Any conclusions or diagnosis should be discussed in depth with the 
patient and family. Patients should be educated on self-management and insulin dose 
adjustments, since a main cause of brittle diabetes is failure of the patient to understand or 
manage his or her own diabetes (Rice, 2006). Effective education should provide knowledge 
within a context with which the patient can become familiar and should do justice to the 
unpredictability and complexity of actual life, as well as to the patient's own individuality 
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(Wroe, 2004). Efficacious education should transcend mechanical transmission of 
information to attain a deeper level of knowledge and inspire sustainable behavior changes 
and this is the only way to progress from incompliance to compliance and assimilation of 
fundamental principles, to active adherence, which is known to result in effective self-
management (Lutfey et al., 1999). Thus, the patient is put in control to cope with the ever-
changing situations of life (Papanas & Maltezos, 2008). 
In recurrent hypoglycemia, all patients and their associates should be educated about the 
prevention and treatment of hypoglycemia (Dagogo-Jack, 2004). Moreover, appropriate 
information about hypoglycemia unawareness should take place upon diagnosis and 
regularly thereafter at follow-up consultations. Patients should be reminded to avoid usual 
behaviors that may contribute to hypoglycemia, such as taking excess insulin, delaying or 
missing meals, mistiming insulin/food intake around exercise, not monitoring before bed 
and appropriate increased food intake. Alcohol consumption can also lead to hypoglycemia 
and impair recovery from a hypoglycemic episode; the importance of not omitting food 
when drinking should be emphasized to patients. Additionally, patients should be advised 
to have a glucagon emergency kit on hand for severe hypoglycemic episodes (Aschner et al., 
2010). Self monitoring of blood glucose can provide valuable information.  
Although hypoglycemia avoidance restores awareness, it is difficult to be sustained. 
Hypoglycemia unawareness increases severe hypoglycemia risk. When adherence to 
treatment changes is compared by awareness status, reduced adherence to changes in 
insulin regimen in patients with hypoglycemia unawareness is compatible with habituation 
to hypoglycemic stress (Ly et al., 2009). Hypoglycemia unawareness in type 1 diabetes is 
largely secondary to recurrent therapeutic hypoglycemia, as assessed by neuroendocrine 
and symptom responses (Janssen et al., 2000) and cognitive function in patients with brittle 
type 1 diabetes and recurrent hypoglycemia (Bolli et al., 1998; Cryer et al., 2009). Reduced 
awareness of hypoglycemia in some patients with overzealous glycemic control may be 
partially restored by reducing insulin dosages and allowing mean blood glucose to rise 
(Fanelli et al., 1993). Respectively, after a short period (~2 weeks) of hypoglycemia 
prevention, the magnitude of symptom and neuroendocrine responses (with the exception 
of glucagon and norepinephrine) nearly normalizes, and cognitive function is deteriorated 
at the same glycemic threshold and to the same extent as in subjects without diabetes. At 3 
months, the glycemic thresholds of symptom and neuroendocrine responses normalize, and 
some of the responses of glucagon are recovered (Fanelli et al., 1994). Hypoglycemia 
unawareness in type 1 diabetes is largely reversible and intensive insulin therapy together 
with a program of intensive education may substantially prevent hypoglycemia and at the 
same time maintain the glycemic targets of intensive insulin therapy in patients with brittle 
type 1 diabetes (Lager et al., 1986). Therapies aimed at reversing repetitive harmful 
behaviors may also be useful to restore hypoglycemia awareness, as well as protection from 
severe hypoglycemia. 
7.2 Psychotherapy 
Proven noncompliance to treatment requires careful handling. The "polarization" of brittle 
diabetic instability into hyperglycemic (recurrent diabetic ketoacidosis) or hypoglycemic 
behavior is well described, with relatively few displaying characteristics of "mixed 
brittleness" (Tattersall et al., 1991, Gill, 1992). Inpatient psychotherapy of patients with 
brittle diabetes and psychic reactions significantly stabilizes and improves blood glucose 
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after separation. Significant predictors for the average blood glucose are the therapist's 
vacation and the announcement of discharge from the hospital. A significant predictor for 
the daily blood glucose variation is mood (Milch et al., 2002). These results suggest the 
benefit of psychotherapy for young patients with brittle diabetes ((Mitchell et al., 2009).  
Psychological therapy improves noncompliance as a primary cause of “brittleness” and in 
most cases patients are completed rehabilitated (Schade et al., 1985; Viner et al., 2003). 
However, in other groups the psychological management of “difficult” diabetes is less 
encouraging (Didjurgeit et al., 2002; Mitchell et al., 2009).  
7.3 Alternative medicine 
The Rauvolfia-Citrus tea is made by the boiling foliage of Rauvolfia vomitoria and the fruits 
of Citrus aurantium and is used to treat diabetes in Nigerian folk medicine. Chronic 
administration of the Rauvolfia-Citrus tea together with antidiabetic medication caused 
significant improvements in markers of glycemic control, such as blood glucose clearance, 
fasting and 2-h postprandial plasma glucose and HbA1c without adverse effects or 
hypoglycemia. Furthermore it ameliorated the fatty acid profile of skeletal muscle 
(Campbell-Tofte et al., 2010).  
On healthy people vinegar delays gastric emptying and lowers postprandial blood glucose 
and insulin levels (Hlebowicz et al., 2008). The effect of 30 ml apple cider vinegar daily 
before breakfast on delayed gastric emptying rate on patients with brittle type 1 diabetes 
was assessed. Vinegar affected patients with diabetic gastroparesis by reducing the gastric 
emptying rate even further, with a concomitant disadvantage regarding to their glycemic 
control (Hlebowicz et al., 2007). 
7.4 Insulin therapy 
Intensive insulin treatment is defined by basal-prandial insulin therapy which tries to 
reproduce physiological insulin secretion. This requires 3 to 5 injections and self-monitoring 
of blood glucose 4 to 5 times a day. Patients who accept their disease and the demanding 
treatment regimen most often achieve glycemic treatment goals. Severe complications of 
diabetes can be avoided without increasing the risk of severe hypoglycemia. However, 
patients with brittle diabetes do not reach this objective (Jacqueminet  et al., 2005). Besides 
the usual reasons affecting all patients with type 1 diabetes, i.e. diabetes itself, the 
idiosyncrasy of the patient, or the physician, in Brittle Diabetes the main obstacle which 
prevents patients from reaching the ideal glycemic target is more often related to 
psychological problems: difficulties in self-regulation, denial of diabetes presence, or phobia 
of hypoglycemia with avoidance behavior. Frequently, young women present eating 
disorders which can explain the poor diabetes control. The physician may be implicated in 
these poor glycemic results by not prescribing the right tools to obtain optimal glycemic 
control (staying with just two daily injections with premixed insulin) or by assigning 
glycemic targets inaccessible for the patient, or when an empathic relationship cannot be 
established between the patient and the physician. Patient empowerment is the key to the 
success of functional insulin treatment. 
Cases of brittle type 1 diabetes in which recurrent hypoglycemia and peripheral edema were 
relieved after conversion from insulin lispro to insulin aspart have been reported (Tone et 
al., 2008) and stable glycemic control, as well as edema-free condition were maintained after 
conversion of insulin analogs. Several studies reported significantly fewer symptomatic 
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episodes of hypoglycemia with insulin aspart than with insulin lispro administrated by 
continuous subcutaneous insulin infusion in type 1 diabetes (Plank et al., 2002), which might 
be due to the differences in their pharmacokinetics and actions (O’Hare et al., 1983).  On the 
other hand, plasma volume, intravascular albumin content and transcapillary escape rate of 
albumin change in response to hypoglycemia were also ameliorated by insulin conversion 
(Hilsted et al., 1991). Therefore, in cases of brittle type 1 diabetes, especially with peripheral 
edema, it may be worth using insulin analogs. 
7.5 Insulin pump therapy 
Though in use for more than 3 decades, insulin pumps are now being more commonly used 
because of their unique ability to continuously infuse insulin, closely mimicking that of 
physiological secretion from a normal pancreas. Unlike insulin shots with syringes, pump 
infusion sites need to be changed less frequently. Insulin pumps are reported to improve 
glycemic control, normalize blood glucose levels, reduce glycemic swings, and the dawn 
phenomenon. Fewer hypoglycemic episodes and a reduction in insulin dose per day are 
reported with insulin pump therapy as well as an improvement in sexual function, libido, 
and a significant relief of the intractable pain of peripheral neuropathy (Kesavadev et al., 
2010). Quality of life is ameliorated by a reduction in the chronic fear of severe 
hypoglycemia, the more flexibility of lifestyle-no need to eat at fixed intervals, more 
freedom of lifestyle and easier participation in social and physical activity, and benefits for 
the patients' family (Cummins et al., 2010). The success of insulin pump therapy depends on 
selection of the right candidate, extensive education, motivation, and implementing the 
sophisticated programs with skill. Long-term follow-up of medical, psychological, and 
neurocognitive parameters in young patients with brittle diabetes have further summarized 
the same efficacy and safety of continuous subcutaneous insulin infusion in children ≤6 
years of age (Eugster et al., 2006).  
Insulin pump therapy can be initiated and used effectively in patients with brittle type 1 
diabetes to improve metabolic control and quality of life. When diabetes and pump 
management are appropriately individualized, this kind of therapy can help patients with 
type 1 diabetes to achieve and to sustain metabolic control. Lifestyle flexibility, quality of life 
improvement, and independence can be maintained throughout young adulthood 
(Petrovski et al, 2007). Nocturnal glycemic control is improved with insulin pumps, and 
automatic basal rate changes help to minimize a pre-breakfast blood glucose increase (the 
"dawn phenomenon") often seen with injection therapy. Implantable pumps have 
advantages for patients who either weight more than 80kgs or have abnormalities of kidney 
or liver function or are highly sensitized. One study compared intraperitoneal insulin 
infusion through an implantable pump with intraportal islet transplantation (Vantyghem et 
al, 2009). Although the metabolic results (HbA1c, daily insulin need, glycemia) improved 
with both methods, they were significantly ameliorated with intraportal islet 
transplantation, though with more frequent side effects (hypoglycemia). 
7.6 Islet transplantation  
Islet cell transplantation is an attractive concept which holds great promise for the treatment 
of type 1 diabetes and for preventing brittle diabetes in patients undergoing pancreatic 
resection; given its potential high efficacy and that it is a relatively noninvasive procedure 
and a smart alternative to pancreas transplantation for restoring endogenous insulin 
www.intechopen.com
 
Brittle Diabetes: A Contemporary Review of the Myth and Its Realization 
 
63 
secretion, islet cell transplantation may effectively control blood glucose for brittle type 1 
diabetes, resulting in a marked reduction in hypoglycemic episodes and improvements in 
glycemic control. In addition, approximately 70% of transplanted patients with type 1 
diabetes have achieved insulin independence (Matsumoto et al, 2005). 
Isolated islet transplantation, which restores glucose sensing, should be considered in cases 
of hypoglycemic unawareness and/or lability especially if the body mass index is 
<25kg/m2, but with current immunosuppressive protocols patients must have normal renal 
function and preferably no plans for pregnancy (Matsumoto et al., 2007). The main limiting 
factor of beta-cell function replacement by transplantation is so far represented by the 
potentially severe side effects of the immunosuppressant therapy necessary to avoid graft 
rejection and recurrence of autoimmunity.  
Advances in islet isolation methods and immunosuppressive regimens are leading to 
expanded clinical trials to develop islet transplantation as a therapeutic option for patients 
with type 1 diabetes (Sumino et al., 2003). However, the isolation process is still potentially 
harmful to the islets (Bottino et al., 2004) because it may expose them to damaging factors 
that induce a general proinflammatory state. Moreover, after transplantation, islets are 
subject to hypoxia and early nonspecific inflammatory events, mostly mediated by the 
recipient’s immune cells that can compromise beta-cell viability and function. Locally 
secreted chemoattractants and proinflammatory molecules might recruit and activate 
immune cells to the transplant site, mediating irreparable damage to the islet graft. Islet 
survival in the early post transplantation period is influenced by inflammatory events in 
and around islets.  
CD40, a member of tumor necrosis factor receptor family expressed mainly in 
nonhematopoietic cells, is generally associated with inflammation. CD40 contributes not only 
to physiological cell-mediated responses, but also to immune pathological conditions such as 
autoimmune and vascular diseases, leading to a chronic inflammatory state. It has been 
previously reported that the CD40 molecule is expressed also in human pancreatic beta-cells 
and that expression can be upregulated by incubation with a cocktail of proinflammatory 
cytokines (Klein et al., 2005). CD40 signals in beta-cells upregulate secretion of interleukin (IL)-
6, IL-8, macrophage inflammatory protein (MIP)-1, and MIP-1β (Barbé-Tuana et al., 2006). 
These results in vitro indicate that the CD40 receptor expressed by beta-cells could be activated 
in vivo inducing proinflammatory responses contributing to early islet graft loss after 
transplantation. In this regard, the use of specific blockers immediately after the isolation 
process could improve islet viability and perhaps clinical success rates. 
Reducing the islet proinflammatory state has been demonstrated to reduce the early post-
transplant complications and perhaps improve islet engraftment (Bertuzzi  et al., 2004). 
Moreover, increased percentage of insulin-independence at 1-year post-transplant and 
decreased percentage of cardiovascular events has been achieved with corticosteroids-
sparing protocols in pancreas islet allotransplantation in patients with brittle diabetes. 
Lympho-depleting induction antibodies, such as rabbit anti-thymocyte globulin or 
alemtuzumab, calcineurin inhibitors and mycophenolate or sirolimus have been widely 
used in successful trials. However, since most of the studies were uncontrolled trials of low-
risk patients and therefore the grade of evidence is limited, large-scale prospective studies 
with long-term follow up are necessary to assess risks and benefits of corticosteroids-
sparing regimens in pancreas transplantation before recommending such strategies as 
standard practice.  
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It is often reported that islets from more than one donor are required to achieved insulin 
independence, even when an acceptable islet mass was transplanted in the first infusion. 
The success of recent clinical trials for allogeneic islet transplantation as well as the 
increasing centers that perform auto-transplantation is showing that the beta-cell 
replacement therapy for the treatment of patients with diabetes or total pancreatectomy has 
been firmly established. It needs only to be improved and made more widely available to 
the millions of desperate patients with brittle diabetes who search for alternatives to a life of 
insulin injections, hypoglycemia and the risks of end-organ damage. Important issues to be 
addressed before this treatment is widely applicable, including difficulty in maintaining 
insulin independence, low islet isolation success rate, multiple donor requirements, and side 
effects associated with the use of immunosuppressants. Steady progress has been achieved 
in recent years in different areas in the pancreatic islet transplantation process including 
islet cell processing, preservation, and immune therapies that justify optimism.  
Combined islet and donor CD34+ hematopoietic stem cell infusion using an 'Edmonton-like' 
immunosuppression (daclizumab, sirolimus, tacrolimus), with a single dose of anti-TNF 
alpha antibody (Infliximab) adds to the induction without ablative conditioning, and may 
lead to stable chimerism and graft tolerance in patients with Brittle Type 1 Diabetes 
receiving a single-donor allogeneic islet transplant (Mineo et al, 2008). A prospective phase 
1/2 trial investigated the safety and reproducibility of allogeneic islet transplantation and 
tested a strategy to achieve insulin-independence with lower islet mass in C-peptide 
negative Brittle Type 1 Diabetes patients with hypoglycemic unawareness. All patients 
received an equal mean total number of islets. Both the Edmonton immunosuppression 
regimen (daclizumab, sirolimus, tacrolimus) and the University of Illinois protocol 
(etanercept, exenatide and the Edmonton regimen) induced insulin-independence. 
However, combined treatment of etanercept and exenatide improved islet graft function 
and facilitates achievement of insulin-independence with fewer islets (Gangemi et al, 2008). 
Optimal primary graft function has been associated with prolonged graft survival and better 
metabolic control (HbA1c, mean glucose, glucose variability assessed with continuous glucose 
monitoring system, and glucose tolerance defined by an oral glucose tolerance test) after islet 
transplantation (Vantyghem et al., 2009). This result was not significantly influenced by HLA 
mismatches or by preexisting islet autoantibodies. A pancreas transplant alone in a nonuremic 
patient with Brittle Diabetes is a rare procedure because the tradeoff for insulin independence 
is lifelong immunosuppression. However, a technically successful pancreas transplant alone is 
currently the only treatment option that allows nonuremic patients with Brittle Diabetes to 
become insulin-independent in the long term. Risk factors for subsequent kidney failure (13% 
at 5 years posttransplant) are serum creatinine levels >1.5 mg/dL at the time of the pancreas 
transplant and recipient age<30 years (Gruessner et al., 2008). 
Donor shortage is another dilemma. To address the issue of donor shortage, living donor 
islet transplantation and bioartificial islet transplantation using pig islets are being 
evaluated. Bioartificial islet transplantation could be the ultimate solution of the donor 
shortage. Currently, overcoming immunological hurdles, establishing reliable islet isolation 
methods, and controlling porcine endogenous retrovirus are the primary obstacles to the 
implementation of this treatment. If bioartificial islet transplant becomes a clinical reality, it 
may even be applicable in the treatment of select patients with Type 2 diabetes. Beta-Cell 
regeneration from naïve pancreas and beta-cell generation from embryonic stem cells or 
induced pluripotent stem cells are poised as the next-generation treatments for Type 1 
diabetes (Matsumoto, 2010). 
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Preemptive simultaneous kidney-pancreas transplantation in patients with Type 1 Brittle 
Diabetes, severe diabetic autonomic neuropathy and nephrotic syndrome due to diabetic 
nephropathy, with near-normal exhibited function of the native kidneys leads to rapid and 
nearly complete diminution of proteinuria although the residual function of the patient's 
native kidneys was reduced from 60% at about 40% at 3 months after transplantation and 
slightly lower at 12 months after simultaneous kidney-pancreas transplantation (Sedlak et 
al, 2007). Besides kidney microcirculation, islet transplantation alone has also a beneficial 
effect on the retinal microcirculation, since recently an early, significant increase of arterial 
and venous retinal blood flow velocities was found 1-year after islet transplantation 
(Venturini et al., 2006). 
However, whether islet transplantation should be aimed at restoring insulin independence 
or providing adequate metabolic control and restoration of diabetic microvascular 
complications is still debated (Badet et al., 2007). Updated summary of results from 
Edmonton procedure and experience with combined results from different institutions 
reported to the Collaborative Islet Transplant Registry have largely substantiated the 
reproducibility of the Edmonton procedure (Ryan et al., 2001). Complete insulin-
independence is achieved in the majority of patients 1-year after transplant (more then 55%) 
but this state is not sustained permanently. Although only a minority (10%) of patients 
remained insulin-free after 5 years, more then 80% of them had still detectable levels of C-
peptide and substantially improved glycemic control without episodes of hypoglycemia. 
Even though currently, the islet graft is still not a remedy for every patient with Brittle 
Diabetes, islet transplantation has already obtained "nonresearch" status and is close to 
having a biological license status approved by the FDA in the United States that would 
further stimulate progress in the field (Witkowski et al., 2006; Alejandro et al., 2008). 
8. Conclusions 
There are many complexities involved in treating patients with brittle diabetes and helping 
them to achieve and maintain their euglycemia. Therefore, adopting a team approach that 
involves a broad range of disciplines is essential. Depending on circumstances and available 
resources, the multidisciplinary team should include the patient, diabetes specialist, primary 
care physician, nurse, dietitian, podiatrist and psychologist/psychiatrist, as well as family 
and friends. All members of the team should work together to ensure continuity of care. 
Communication and coordination within the team are also imperative to ensure that all 
members share and are working towards the same treatment targets and recommendations. 
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